WinSanTor

WinSanTor is a clinical-stage biotechnology company focused on accelerating development of the first treatment to prevent and reverse peripheral neuropathy, beginning with diabetic peripheral neuropathy. Currently, there is no U.S. FDA-approved treatment for diabetic neuropathy, a condition that afflicts over 420 million worldwide who suffer from diabetes. WinSanTor's lead compound, WST-057, is a well-characterized previously-approved drug with an established safety history that has been used for many years against an unrelated indication. The company is also investigating the drug's potential to treat other common forms of peripheral neuropathy. WinSanTor was founded with the vision that recent scientific insights into the biological processes underlying degenerative diseases offer an unprecedented opportunity to discover and develop effective medicines.